Ubiquitin C-terminal hydrolase L1 (UCHL1) is a neuronal protein important in maintaining axonal integrity and motor function and may be important in the pathogenesis of many neurological disorders. UCHL1 may ameliorate acute injury and improve recovery after cerebral ischemia. In the current study, the hypothesis that UCHL1’s hydrolase activity underlies its effect in maintaining axonal integrity and function is tested after ischemic injury. Hydrolase activity was inhibited by treatment with a UCHL1 hydrolase inhibitor or by employing knockin mice bearing a mutation in the hydrolase active site (C90A). Ischemic injury was induced by oxygen-glucose deprivation (OGD) in brain slice preparations and by transient middle cerebral artery occlusion (tMCAO) surgery in mice. Hydrolase activity inhibition increased restoration time and decreased the amplitude of evoked axonal responses in the corpus callosum after OGD. Mutation of the hydrolase active site exacerbated white matter injury as detected by SMI32 immunohistochemistry, and motor deficits as detected by beam balance and cylinder testing after tMCAO. These results demonstrate that UCHL1 hydrolase activity ameliorates white matter injury and functional deficits after acute ischemic injury and support the hypothesis that UCHL1 activity plays a significant role in preserving white matter integrity and recovery of function after cerebral ischemia.
FisherMFeuersteinGHowellsDW, et al.
Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke2009;
40: 2244–2250.
2.
WangYLiuGHongD, et al.
White matter injury in ischemic stroke. Prog Neurobiol2016;
141: 45–60.
3.
XuSYPanSY.The failure of animal models of neuroprotection in acute ischemic stroke to translate to clinical efficacy. Med Sci Monit Basic Res2013;
19: 37–45.
4.
ChengYDAl-KhouryLZivinJA.Neuroprotection for ischemic stroke: two decades of success and failure. NeuroRx2004;
1: 36–45.
5.
BishopPRubinPThomsonAR, et al.
The ubiquitin C-terminal hydrolase L1 (UCH-L1) C terminus plays a key role in protein stability, but its farnesylation is not required for membrane association in primary neurons. J Biol Chem2014;
289: 36140–36149.
6.
MiZGrahamSH.Role of UCHL1 in the pathogenesis of neurodegenerative diseases and brain injury. Ageing Res Rev2023;
86: 101856.
KoharudinLMLiuHDi MaioR, et al.
Cyclopentenone prostaglandin-induced unfolding and aggregation of the Parkinson disease-associated UCH-L1. Proc Natl Acad Sci U S A2010;
107: 6835–6840.
9.
CastegnaAAksenovMAksenovaM, et al.
Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic Biol Med2002;
33: 562–571.
10.
ChoiJLeveyAIWeintraubST, et al.
Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J Biol Chem2004;
279: 13256–13264.
11.
LiuYFallonLLashuelHA, et al.
The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell2002;
111: 209–218. Jr.
12.
SultanaRBoyd-KimballDPoonHF, et al.
Redox proteomics identification of oxidized proteins in Alzheimer's disease hippocampus and cerebellum: an approach to understand pathological and biochemical alterations in AD. Neurobiol Aging2006;
27: 1564–1576.
13.
GuglielmottoMMonteleoneDVasciaveoV, et al.
The decrease of Uch-L1 activity is a common mechanism responsible for abeta 42 accumulation in Alzheimer's and vascular disease. Front Aging Neurosci2017;
9: 320.
14.
LiuHPovyshevaNRoseME, et al.
Role of UCHL1 in axonal injury and functional recovery after cerebral ischemia. Proc Natl Acad Sci U S A2019;
116: 4643–4650.
15.
Percie Du SertNHurstVAhluwaliaA, et al.
The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. J Cereb Blood Flow Metab2020;
40: 1769–1777.
16.
LiuHLiWRoseME, et al.
The point mutation UCH-L1 C152A protects primary neurons against cyclopentenone prostaglandin-induced cytotoxicity: implications for post-ischemic neuronal injury. Cell Death Dis2015;
6: e1966.
17.
MiZLiuHRoseME, et al.
Mutation of a ubiquitin carboxy terminal hydrolase L1 lipid binding site alleviates cell death, axonal injury, and behavioral deficits after traumatic brain injury in mice. Neuroscience2021;
475: 127–136.
18.
LiuHChenWLiangC, et al.
WP1130 increases doxorubicin sensitivity in hepatocellular carcinoma cells through usp9x-dependent p53 degradation. Cancer Lett2015;
361: 218–225.
19.
BakerAJPhanNMoultonRJ, et al.
Attenuation of the electrophysiological function of the corpus callosum after fluid percussion injury in the rat. J Neurotrauma2002;
19: 587–599.
20.
ReevesTMPhillipsLLPovlishockJT.Myelinated and unmyelinated axons of the corpus callosum differ in vulnerability and functional recovery following traumatic brain injury. Exp Neurol2005;
196: 126–137.
21.
TekkokSBGoldbergMP.Ampa/kainate receptor activation mediates hypoxic oligodendrocyte death and axonal injury in cerebral white matter. J Neurosci2001;
21: 4237–4248.
22.
ZhangJBhuiyanMIHZhangT, et al.
Modulation of brain cation-Cl(-) cotransport via the SPAK kinase inhibitor ZT-1a. Nat Commun2020;
11: 78.
23.
DixonCELyethBGPovlishockJT, et al.
A fluid percussion model of experimental brain injury in the rat. J Neurosurg1987;
67: 110–119.
24.
FeeneyDMBoyesonMGLinnRT, et al.
Responses to cortical injury: I. Methodology and local effects of contusions in the rat. Brain Res1981;
211: 67–77.
25.
SchallertTFlemingSMLeasureJL, et al.
CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology2000;
39: 777–787.
26.
KimEWooMSQinL, et al.
Daidzein augments cholesterol homeostasis via ApoE to promote functional recovery in chronic stroke. J Neurosci2015;
35: 15113–15126.
27.
MiZLiuHRoseME, et al.
Abolishing UCHL1's hydrolase activity exacerbates TBI-induced axonal injury and neuronal death in mice. Exp Neurol2021;
336: 113524.
28.
MuH-FGaoX-GLiS-C, et al.
Distinctive functional deficiencies in axonal conduction associated with two forms of cerebral white matter injury. CNS Neurosci Ther2019;
25: 1018–1029.
29.
BhuiyanMIHYoungCBJahanI, et al.
NF-kappaB signaling-mediated activation of WNK-SPAK-NKCC1 Cascade in worsened stroke outcomes of ang II-Hypertensive mice. Stroke. Stroke2022;
53: 1720–1734.
30.
KellerJNHuangFFZhuH, et al.
Oxidative stress-associated impairment of proteasome activity during ischemia-reperfusion injury. J Cereb Blood Flow Metab2000;
20: 1467–1473.
31.
WilsonPOBarberPCHamidQA, et al.
The immunolocalization of protein gene product 9.5 using rabbit polyclonal and mouse monoclonal antibodies. Br J Exp Pathol1988;
69: 91–104.
32.
DayINThompsonRJ.UCHL1 (PGP 9.5): neuronal biomarker and ubiquitin system protein. Prog Neurobiol2010;
90: 327–362.
33.
SaigohKWangYLSuhJG, et al.
Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice. Nat Genet1999;
23: 47–51.
34.
WaltersBJCampbellSLChenPC, et al.
Differential effects of Usp14 and Uch-L1 on the ubiquitin proteasome system and synaptic activity. Mol Cell Neurosci2008;
39: 539–548.
35.
CoulombeJGamagePGrayMT, et al.
Loss of UCHL1 promotes age-related degenerative changes in the enteric nervous system. Front Aging Neurosci2014;
6: 129.
36.
ReinickeATLabanKSachsM, et al.
Ubiquitin C-terminal hydrolase L1 (UCH-L1) loss causes neurodegeneration by altering protein turnover in the first postnatal weeks. Proc Natl Acad Sci U S A2019;
116: 7963–7972.
37.
YamazakiKWakasugiNTomitaT, et al.
Gracile axonal dystrophy (GAD), a new neurological mutant in the mouse. Proc Soc Exp Biol Med1988;
187: 209–215.
38.
GençBJaraJHSanchezSS, et al.
Upper motor neurons are a target for gene therapy and UCHL1 is necessary and sufficient to improve cellular integrity of diseased upper motor neurons. Gene Ther2022;
29: 178–192.
39.
DingLChuWXiaY, et al.
UCHL1 facilitates protein aggregates clearance to enhance neural stem cell activation in spinal cord injury. Cell Death Dis2023;
14: 479.
40.
ShenHSikorskaMLeblancJ, et al.
Oxidative stress regulated expression of ubiquitin carboxyl-terminal hydrolase-L1: role in cell survival. Apoptosis2006;
11: 1049–1059.
41.
LiuHLiWAhmadM, et al.
Modification of ubiquitin-C-terminal hydrolase-L1 by cyclopentenone prostaglandins exacerbates hypoxic injury. Neurobiol Dis2011;
41: 318–328.
42.
GrahamSHLiuH.Life and death in the trash heap: the ubiquitin proteasome pathway and UCHL1 in brain aging, neurodegenerative disease and cerebral ischemia. Ageing Res Rev2017;
34: 30–38.
43.
HuBRJanelidzeSGinsbergMD, et al.
Protein aggregation after focal brain ischemia and reperfusion. J Cereb Blood Flow Metab2001;
21: 865–875.
44.
HuBRMartoneMEJonesYZ, et al.
Protein aggregation after transient cerebral ischemia. J Neurosci2000;
20: 3191–3199.
45.
KahlesTPoonCQianL, et al.
Elevated post-ischemic ubiquitination results from suppression of deubiquitinase activity and not proteasome inhibition. Cell Mol Life Sci2021;
78: 2169–2183.
46.
LiuHRoseMEMaX, et al.
In vivo transduction of neurons with TAT-UCH-L1 protects brain against controlled cortical impact injury. PloS One2017;
12: e0178049.
47.
ChenCQinHTanJ, et al.
The role of ubiquitin-proteasome pathway and autophagy-lysosome pathway in cerebral ischemia. Oxid Med Cell Longev2020;
2020: 5457049.
48.
BilguvarKTyagiNKOzkaraC, et al.
Recessive loss of function of the neuronal ubiquitin hydrolase UCHL1 leads to early-onset progressive neurodegeneration. Proc Natl Acad Sci U S A2013;
110: 3489–3494.
49.
KabutaTWadaK.Insights into links between familial and sporadic Parkinson's disease: physical relationship between UCH-L1 variants and chaperone-mediated autophagy. Autophagy2008;
4: 827–829.
50.
RydningSLBackePHSousaMML, et al.
Novel UCHL1 mutations reveal new insights into ubiquitin processing. Hum Mol Genet2017;
26: 1217–1218.
51.
ImaizumiTKocsisJDWaxmanSG.Anoxic injury in the rat spinal cord: pharmacological evidence for multiple steps in Ca(2+)-dependent injury of the dorsal columns. J Neurotrauma1997;
14: 299–311.
52.
StutzmannJMPrattJBoraudT, et al.
The effect of riluzole on post-traumatic spinal cord injury in the rat. Neuroreport1996;
7: 387–392.
53.
PaulSCandelario-JalilE.Emerging neuroprotective strategies for the treatment of ischemic stroke: an overview of clinical and preclinical studies. Exp Neurol2021;
335: 113518.
54.
GladstoneDJBlackSEHakimAM.Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke2002;
33: 2123–2136.
55.
ChenJVenkatPZacharekA, et al.
Neurorestorative therapy for stroke. Front Hum Neurosci2014;
8: 382.
56.
CuiY, JXChoiDJChoiJY, et al.
Axonal degeneration in an in vitro model of ischemic white matter injury. Neurobiol Dis2020;
134: 104672.
57.
HuuskonenMTWangYNikolakopoulouAM, et al.
Protection of ischemic white matter and oligodendrocytes in mice by 3K3A-activated protein C. J Exp Med2022;
219: e20211372.
58.
LiuYHeYZhangJ, et al.
White matter injury: an emerging potential target for treatment after subarachnoid hemorrhage. Oxid Med Cell Longev2023;
2023: 3842493.
59.
McDonaldJWAlthomsonsSPHyrcKL, et al.
Oligodendrocytes from forebrain are highly vulnerable to AMPA/kainate receptor-mediated excitotoxicity. Nat Med1998;
4: 291–297.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
